Anti-HPV vaccination: A review of recent economic data for Italy |
| |
| Authors: | F.S. Mennini S. Costa G. Favato M. Picardo |
| |
| Affiliation: | 1. CEIS Sanità (Centre for Health Economics and Management – CHEM), Faculty of Economics, University of Rome, Tor Vergata, Rome, Italy;2. Department of Obstetrics and Gynaecology, Hospital S. Orsola-Malpighi, Bologna, Italy;3. School of Projects, Processes and Systems, Henley Management College, Henley, UK;4. Laboratory of Cutaneous Pathophysiology, San Gallicano Dermatological Institute (IRCCS), Rome, Italy |
| |
| Abstract: | The total cost of HPV-related diseases accounts for €200–250 million of which €210 million is absorbed by the prevention and treatment of precancerous lesions and cervical cancer.Although both available HPV vaccines are below the threshold value for economic convenience (€9,569 and €26,361 per QALY-gained for the quadrivalent and bivalent vaccines, respectively), at this point in time long-term economic models developed for Italy seem to indicate the quadrivalent vaccine as the most cost-effective option.Recent publications by official bodies, including the World Health Organization and the Supervisory Authority for Public Contracts in Italy, recommend that the decision-making process be based on both the quality of goods and services as well as the best achievable price. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
